Eosinophil-Driven Diseases (EDDs)
Expanding the reach of our medicines to address unmet needs
Our commitment to eosinophil-driven diseases
We are committed to developing medicines for eosinophil-driven diseases (EDDs) where there is a clear unmet treatment need, with the ambition to improve the health outcomes and lives of millions of patients worldwide who face these debilitating, potentially fatal illnesses.1,2
EDDs are inflammatory illnesses in which elevated eosinophils are a direct cause or are thought to play a critical role.3 They include eosinophilic esophagitis, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome and some types of nasal polyposis, severe asthma and chronic obstructive pulmonary disease.
Some EDDs have limited or no approved treatment options, creating a significant unmet need for innovative medicines.
– Living with Eosinophilic Esophagitis (EoE)
“It was pretty terrifying to not be able to go out and eat and take my wife anywhere without worrying about getting home...or having severe abdominal pain so bad that it just made you bend over in a ball.”
– Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
“Before this, I was a career person and I exercised a lot and now I can’t do any of that anymore. Your friends kind of disappear when you get sick because nobody wants to sit on your couch constantly and watch movies, but that’s pretty much what you can do. It’s hard for you to get up and do things."
– Living with Hypereosinophilic Syndrome (HES)
“Between 2010 and 2014, I was hospitalised 26 times. They thought I had been in a fire because that’s the way my skin looked. It looked like someone whose skin had been burned and really what caused that was my excessive scratching and bleeding.”
Types of eosinophil-driven diseases
We are currently investigating the potential within our biologics portfolio to treat inflammatory, EDDs where patients could benefit from innovative medicines.
At AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. Join us and help deliver life-changing medicines. Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
1. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Accessed 20 November 2018. https: apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/.
2. American Partnership for Eosinophilic Disorders. Hypereosinophilic Syndromes. Accessed 16 September 2019. https://apfed.org/about-ead/hypereosinophilic-syndrome/.
3. American Partnership for Eosinophilic Disorders. What is an eosinophil associated disease? Accessed 16 September 2019. https://apfed.org/about-ead/what-is-an-eosinophil-associated-disease/
4. American Partnership for Eosinophilic Disorders. EoE. Accessed 16 September 2019. https://apfed.org/about-ead/egids/eoe/.
5. Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010; 36: 527-543.
6. American Academy of Allergy Asthma & Immunology. Nasal Polyps. Accessed 16 September 2019. https://aaaai.org/conditions-and-treatments/conditions-dictionary/Nasal-Polyps
Veeva ID: Z4-12506
Date of next review: 04/09/2021